Study demonstrates major economic health benefit of PromarkerD – PromarkerD reimbursement update
Independent modelling estimates instigating PromarkerD testing could produce net savings for US payors of US$862 million over four years per million type 2 diabetes patients tested.
The study provides validation of the potential economic health benefit of PromarkerD in diabetic kidney disease management, which improves the likelihood that the test will be reimbursed by payors.
Proteomics International to seek a CPT Proprietary Laboratory Analyses (PLA) code to facilitate the reimbursement of the innovative PromarkerD test by payors in the US.